Therapeutic Potential of Lactoferrin-coated Iron Oxide Nanospheres for Targeted Hyperthermia in Gastric Cancer

Overview

Journal Sci Rep

Specialty Science

Date 2023 Oct 19

PMID 37857677

Authors

Komal Attri

Bhupendra Chudasama

Roop L Mahajan

Diptiman Choudhury

Affiliations

Soon will be listed here.

Abstract

Lactoferrin (LF) is a non-heme iron-binding glycoprotein involved in the transport of iron in blood plasma. In addition, it has many biological functions, including antibacterial, antiviral, antimicrobial, antiparasitic, and, importantly, antitumor properties. In this study, we have investigated the potential of employing lactoferrin-iron oxide nanoparticles (LF-IONPs) as a treatment modality for gastric cancer. The study confirms the formation of LF-IONPs with a spherical shape and an average size of 5 ± 2 nm, embedded within the protein matrix. FTIR and Raman analysis revealed that the Fe-O bond stabilized the protein particle interactions. Further, we conducted hyperthermia studies to ascertain whether the proposed composite can generate a sufficient rise in temperature at a low frequency. The results confirmed that we can achieve a temperature rise of about 7 °C at 242.4 kHz, which can be further harnessed for gastric cancer treatment. The particles were further tested for their anti-cancer activity on AGS cells, with and without hyperthermia. Results indicate that LF-IONPs (10 µg/ml) significantly enhance cytotoxicity, resulting in the demise of 67.75 ± 5.2% of cells post hyperthermia, while also exhibiting an inhibitory effect on cell migration compared to control cells, with the most inhibition observed after 36 h of treatment. These findings suggest the potential of LF-IONPs in targeted hyperthermia treatment of gastric cancer.

Citing Articles

Perturbation of hyperthermia resistance in gastric cancer by hyperstimulation of autophagy using artemisinin-protected iron-oxide nanoparticles.

Attri K, Chudasama B, Mahajan R, Choudhury D RSC Adv. 2024; 14(47):34565-34577.

PMID: 39479497 PMC: 11520311. DOI: 10.1039/d4ra05611f.

HCMV detection in Asian gastric cancer RNA-seq data sets and clinical validation in Indian GC patients reveals the HCMV-GC specific gene signatures.

Krishnamoorthy P, Raj A, Das N, Chenkual S, Pautu J, Ralte L mSystems. 2024; 9(10):e0067324.

PMID: 39283078 PMC: 11494955. DOI: 10.1128/msystems.00673-24.

A Comprehensive Review of Nanoparticles: From Classification to Application and Toxicity.

Eker F, Duman H, Akdasci E, Bolat E, Saritas S, Karav S Molecules. 2024; 29(15).

PMID: 39124888 PMC: 11314082. DOI: 10.3390/molecules29153482.

Metallic nanomaterials - targeted drug delivery approaches for improved bioavailability, reduced side toxicity, and enhanced patient outcomes.

Croitoru G, Pirvulescu D, Niculescu A, Grumezescu A, Antohi A, Nicolae C Rom J Morphol Embryol. 2024; 65(2):145-158.

PMID: 39020529 PMC: 11384046. DOI: 10.47162/RJME.65.2.01.

Integrated insulin-iron nanoparticles: a multi-modal approach for receptor-specific bioimaging, reactive oxygen species scavenging, and wound healing.

Attri K, Chudasama B, Mahajan R, Choudhury D Discov Nano. 2024; 19(1):96.

PMID: 38814485 PMC: 11139842. DOI: 10.1186/s11671-024-04024-6.

References

Sharda D, Attri K, Kaur P, Choudhury D . Protection of lead-induced cytotoxicity using paramagnetic nickel-insulin quantum clusters. RSC Adv. 2022; 11(40):24656-24668. PMC: 9036906. DOI: 10.1039/d1ra03597e. View

Nitin N, LaConte L, Zurkiya O, Hu X, Bao G . Functionalization and peptide-based delivery of magnetic nanoparticles as an intracellular MRI contrast agent. J Biol Inorg Chem. 2004; 9(6):706-12. DOI: 10.1007/s00775-004-0560-1. View

Gibbons J, Kanwar J, Kanwar R . Iron-free and iron-saturated bovine lactoferrin inhibit survivin expression and differentially modulate apoptosis in breast cancer. BMC Cancer. 2015; 15:425. PMC: 4440599. DOI: 10.1186/s12885-015-1441-4. View

Tanaka T, Kawabata K, Kohno H, Honjo S, Murakami M, Ota T . Chemopreventive effect of bovine lactoferrin on 4-nitroquinoline 1-oxide-induced tongue carcinogenesis in male F344 rats. Jpn J Cancer Res. 2000; 91(1):25-33. PMC: 5926223. DOI: 10.1111/j.1349-7006.2000.tb00856.x. View

Iafisco M, Di Foggia M, Bonora S, Prat M, Roveri N . Adsorption and spectroscopic characterization of lactoferrin on hydroxyapatite nanocrystals. Dalton Trans. 2010; 40(4):820-7. DOI: 10.1039/c0dt00714e. View

Chertok B, Moffat B, David A, Yu F, Bergemann C, Ross B . Iron oxide nanoparticles as a drug delivery vehicle for MRI monitored magnetic targeting of brain tumors. Biomaterials. 2007; 29(4):487-96. PMC: 2761681. DOI: 10.1016/j.biomaterials.2007.08.050. View

Lin Y, Cheng C, Shih C, Hwang J, Yu C, Lu C . MIB: Metal Ion-Binding Site Prediction and Docking Server. J Chem Inf Model. 2016; 56(12):2287-2291. DOI: 10.1021/acs.jcim.6b00407. View

El-Fakharany E . Nanoformulation of lactoferrin potentiates its activity and enhances novel biotechnological applications. Int J Biol Macromol. 2020; 165(Pt A):970-984. DOI: 10.1016/j.ijbiomac.2020.09.235. View

Malone R, Felgner P, Verma I . Cationic liposome-mediated RNA transfection. Proc Natl Acad Sci U S A. 1989; 86(16):6077-81. PMC: 297778. DOI: 10.1073/pnas.86.16.6077. View

10.

Murzin A, Brenner S, Hubbard T, Chothia C . SCOP: a structural classification of proteins database for the investigation of sequences and structures. J Mol Biol. 1995; 247(4):536-40. DOI: 10.1006/jmbi.1995.0159. View

11.

Nakamura-Bencomo S, Gutierrez D, Robles-Escajeda E, Iglesias-Figueroa B, Siqueiros-Cendon T, Espinoza-Sanchez E . Recombinant human lactoferrin carrying humanized glycosylation exhibits antileukemia selective cytotoxicity, microfilament disruption, cell cycle arrest, and apoptosis activities. Invest New Drugs. 2020; 39(2):400-415. PMC: 8939434. DOI: 10.1007/s10637-020-01020-2. View

12.

Dashper S, Pan Y, Veith P, Chen Y, Toh E, Liu S . Lactoferrin inhibits Porphyromonas gingivalis proteinases and has sustained biofilm inhibitory activity. Antimicrob Agents Chemother. 2012; 56(3):1548-56. PMC: 3294922. DOI: 10.1128/AAC.05100-11. View

13.

Henikoff S, Henikoff J . Amino acid substitution matrices from protein blocks. Proc Natl Acad Sci U S A. 1992; 89(22):10915-9. PMC: 50453. DOI: 10.1073/pnas.89.22.10915. View

14.

Pomastowski P, Sprynskyy M, Zuvela P, Rafinska K, Milanowski M, Liu J . Silver-Lactoferrin Nanocomplexes as a Potent Antimicrobial Agent. J Am Chem Soc. 2016; 138(25):7899-909. DOI: 10.1021/jacs.6b02699. View

15.

Iglesias-Figueroa B, Siqueiros-Cendon T, Gutierrez D, Aguilera R, Espinoza-Sanchez E, Arevalo-Gallegos S . Recombinant human lactoferrin induces apoptosis, disruption of F-actin structure and cell cycle arrest with selective cytotoxicity on human triple negative breast cancer cells. Apoptosis. 2019; 24(7-8):562-577. PMC: 8935999. DOI: 10.1007/s10495-019-01539-7. View

16.

Jain T, Richey J, Strand M, Leslie-Pelecky D, Flask C, Labhasetwar V . Magnetic nanoparticles with dual functional properties: drug delivery and magnetic resonance imaging. Biomaterials. 2008; 29(29):4012-21. PMC: 2593647. DOI: 10.1016/j.biomaterials.2008.07.004. View

17.

Kaur P, Sharma S, Choudhury S, Singh D, Sharma S, Gadhave K . Insulin-copper quantum clusters preparation and receptor targeted bioimaging. Colloids Surf B Biointerfaces. 2020; 188:110785. DOI: 10.1016/j.colsurfb.2020.110785. View

18.

Sanchez L, Calvo M, Brock J . Biological role of lactoferrin. Arch Dis Child. 1992; 67(5):657-61. PMC: 1793702. DOI: 10.1136/adc.67.5.657. View

19.

Dutz S, Hergt R . Magnetic nanoparticle heating and heat transfer on a microscale: Basic principles, realities and physical limitations of hyperthermia for tumour therapy. Int J Hyperthermia. 2013; 29(8):790-800. DOI: 10.3109/02656736.2013.822993. View

20.

Bruggmoser G, Bauchowitz S, Canters R, Crezee H, Ehmann M, Gellermann J . Guideline for the clinical application, documentation and analysis of clinical studies for regional deep hyperthermia: quality management in regional deep hyperthermia. Strahlenther Onkol. 2012; 188 Suppl 2:198-211. DOI: 10.1007/s00066-012-0176-2. View